Clinical Investigations

Preeclampsia is a major contributor to adverse pregnancy outcomes for both mother and baby. A major difficulty is diagnosing the illness before the conditions are too severe. Previous studies have demonstrated that placental growth factor and vascular endothelial growth factor levels are reduced in women who will develop severe preeclampsia. Current investigations are underway examining the clinical possibilities of early diagnosis of preeclampsia in hopes that treatment modalities will then be possible to prevent the disease.

Other investigations examine the pharmacokinetics of antiseizure, anti-HIV, ACE inhibitors, anticoagulants, nanomedicines and biotech products concerning maternal/ fetal exposures.

Project Collaborators:

• Dr. Kjersti Aagaard
  Baylor College of Medicine, Houston, TX
• Dr. Emily Barrett
• Dr. Robert Brent
  Jefferson Medical College, Philadelphia, PA
• Dr. Christina Chambers
  University of California at San Diego, San Diego, CA
• Dr. Jia Chen
  Icahn School of Medicine at Mt. Sinai, New York City, NY.
• Dr. Thomas Darrah
  The Ohio State University, Columbus, OH
• Dr. Timothy Dye
• Dr. Alan Friedman
• Dr. Philip Katzman
• Dr. Gideon Koren
  Hospital for Sick Children, Toronto, Ca
• Dr. Philip Landrigan
  Icahn School of Medicine at Mt. Sinai, New York City, NY
• Dr. An Li
  University of Illinois at Chicago, Chicago, Illinois

• Dr. Morton Miller
• Dr. John Moye
  National Institutes of Health, Bethesda,MD
• Dr. Shawn Murphy
• Dr. David Oakes
• Dr. Thomas O'Connor
• Dr. Asher Ornoy
  Hadassah Medical School, Hebrew University, Jerusalem, Israel
• Dr. Eva Pressman
• Dr. Carolyn Salafia
  Placenta Analytics, Inc.
• Dr. Eric Schadt
  Icahn School of Medicine at Mt. Sinai, New York City, NY
• Dr. Christopher Stodgell
• Dr. Cheryl Walker
  University of California at Davis, Davis, CA
• Dr. David Wang
• Dr. Ronald Wood

« back to all projects